Search results
Results from the WOW.Com Content Network
In early 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval to a new Alzheimer’s drug called Leqembi. (Biogen, a biotechnology company, and Eisai, a pharmaceutical ...
With full FDA approval for the groundbreaking Alzheimer’s drug Leqembi, Medicare coverage takes a big step forward into a new era of treatment.
Leqembi, which won full U.S. regulatory approval last month, is the first treatment proven to slow progression of the mind-robbing disease for people in the earliest stages of Alzheimer's.
Starting Jan. 1, millions of Americans who get their prescription drugs through Medicare could get a major financial break when a $2,000 out-of-pocket spending cap on medications goes into effect.
The change, which CMS Administrator Chiquita Brooks-LaSure announced in a news release, is a win for advocacy groups, including the Alzheimer's Association, that have been seeking broader access ...
In 2017 Ohio State announced plans for the development of a new hospital and several large ambulatory centers. The new medical tower will include more than 800 beds, 60 neonatal intensive care unit bassinets, and state-of-the-art inpatient service areas. University leaders hope the new hospital tower will be completed by 2025. [4]
Because it is a disease of aging, most Alzheimer's patients are covered by Medicare, which had effectively denied coverage of Leqembi under the accelerated approval it received in January. The ...
An Alzheimer’s disease drug may soon have a new dosing schedule. The medication, Leqembi, is currently administered via an infusion every two weeks. Under the proposed changes, the medication ...